Skip to content

Observance of Anticonvulsant Treatments and Quality of Life of Epileptic Children

Observance of Anticonvulsant Treatments and Quality of Life of Epileptic Children

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03753035
Acronym
ObEPI
Enrollment
75
Registered
2018-11-26
Start date
2018-11-29
Completion date
2019-09-30
Last updated
2019-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children, Only, Epilepsy, Patient Compliance, Quality of Life, Seizures

Keywords

epilepsy, children, seizures, patient compliance, quality of life

Brief summary

There is little epidemiological data in the literature on the therapeutic compliance of epileptic children. Yet it is a fundamental issue in the therapeutic education and balance of this pathology. To obtain more epidemiological precision on the observance of epileptic children and to propose, according to the factors involved, the improvement of practices (therapeutic education ..). Propose an evaluation of the quality of life of their children by a suitable self-questionnaire.

Interventions

None listed

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to 18 Years

Inclusion criteria

* • Child aged 5 to 17 * Child who has received complete information on the organization of the research and who has not objected to his participation and the exploitation of his data * Holder (s) of the parental authority present (s) having received the complete information on the organization of the research and not being opposed to the participation and the exploitation of the data of his child * Epileptic child * Follow-up at the neuro pediatric department of CHRU Nancy

Exclusion criteria

* epileptic encephalopathy * Multiply handicapped child

Design outcomes

Primary

MeasureTime frameDescription
Mean compliance6 monthsMean compliance score measured by the validated Modified Morisky Medication Adherence Scales 8 for epileptic patients 11 subscale with a 5-point Likert scale. According to the scoring system for the MMAS, 8=high adherence, 6 to \<8=medium adherence, and \<6=low adherence. Patients who had a low or a moderate rate of adherence were considered nonadherent5.

Secondary

MeasureTime frameDescription
Compliance score of the modified Modified Morisky Medication Adherence Scales 86 monthsdistribution of responses to new items of the modified MMAS8 scale, internal structure)
quality of life of epileptic children6 monthsQuality of life score measured by the IImpact of Pediatric Epilepsy Scale An 11-item scale was created for children and/or parents' use (according to age) to evaluate the influence of epilepsy on the major aspects of their family and child's life 5 items scale with a 5 point Likert scale
syndromes6 monthsMMAS8 compliance score according to syndromes and equilibrium of epilepsy

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026